| Literature DB >> 26607656 |
Tien-Jyun Chang1, Yen-Feng Chiu2, Wayne H-H Sheu3, Kuang-Chung Shih4, Chii-Min Hwu5,6, Thomas Quertermous7, Yuh-Shan Jou8, Shan-Shan Kuo1, Yi-Cheng Chang1,9, Lee-Ming Chuang1,10.
Abstract
Proprotein convertase subtilisin/kexin type 2 (PCSK2) is a prohormone processing enzyme involved in insulin and glucagon biosynthesis. We previously found the genetic polymorphism of PCSK2 on chromosome 20 was responsible for the linkage peak of several glucose homeostasis parameters. The aim of this study is to investigate the association between genetic variants of PCSK2 and glucose homeostasis parameters and incident diabetes. Total 1142 Chinese participants were recruited from the Stanford Asia-Pacific Program for Hypertension and Insulin Resistance (SAPPHIRe) family study, and 759 participants were followed up for 5 years. Ten SNPs of the PCSK2 gene were genotyped. Variants of rs6044695 and rs2284912 were associated with fasting plasma glucose, and variants of rs2269023 were associated with fasting plasma glucose and 1-hour plasma glucose during OGTT. Haplotypes of rs4814605/rs1078199 were associated with fasting plasma insulin levels and HOMA-IR. Haplotypes of rs890609/rs2269023 were also associated with fasting plasma glucose, fasting insulin and HOMA-IR. In the longitudinal study, we found individuals carrying TA/AA genotypes of rs6044695 or TC/CC genotypes of rs2284912 had lower incidence of diabetes during the 5-year follow-up. Our results indicated that PCSK2 gene polymorphisms are associated with pleiotropic effects on various traits of glucose homeostasis and incident diabetes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26607656 PMCID: PMC4660384 DOI: 10.1038/srep14380
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the SAPPHIRe Chinese participants.
| Variables | Baseline | Follow-up | ||
|---|---|---|---|---|
| N | Mean ± SD | N | Mean ± SD | |
| Age | 1144 | 48.35 ± 9.09 | 759 | 53.18 ± 9.51 |
| Gender (male, %) | 537 | 46.94 | 348 | 45.85 |
| BMI (kg/m2) | 935 | 24.96 ± 3.43 | 678 | 25.46 ± 3.49 |
| FPG (mmol/l) | 1136 | 88.52 ± 10.62 | 671 | 95.98 ± 23.09 |
| 1 h-PG (mmol/l) | 1040 | 166.45 ± 40.39 | 629 | 187.99 ± 49.58 |
| 2 h PG (mmol/l) | 1023 | 127.98 ± 32.47 | 632 | 148.55 ± 52.03 |
| FINS (pmol/l) | 1133 | 7.37 ± 5.47 | 674 | 6.58 ± 5.41 |
| 1 h INS (pmol/l) | 1039 | 77.26 ± 56.3 | 632 | 84.53 ± 66.83 |
| 2 h INS (pmol/l) | 1042 | 61.5 ± 55.58 | 633 | 72.39 ± 66.75 |
| HOMA-IR | 1132 | 1.65 ± 1.35 | 669 | 1.63 ± 1.56 |
| HOMA-beta | 1112 | 117.76 ± 119.59 | 663 | 90.03 ± 144.45 |
| AUCg (mmol*hr/l) | 1014 | 296.4 ± 56.83 | 629 | 333.48 ± 82.34 |
| AUCi (pmol*hr/l) | 1031 | 111.88 ± 78.97 | NA | NA |
BMI: body mass index, AUCg: area under curve of plasma glucose, FPG: fasting plasma glucose concentration, 1 h-PG: 1 hr plasma glucose concentration during OGTT, 2 h-PG: 2 hr plasma glucose concentration during OGTT, FINS: fasting plasma insulin concentration, 1 h-INS: 1 hr plasma insulin concentration during OGTT, 2 h-INS: 2 hr plasma insulin concentration during OGTT, AUCg: area under curve of plasma glucose, AUCi: Area under curve of plasma insulin.
Family-based association test of PCSK2 SNPs with glucose homeostasis in SAPPHIRe Chinese.
| SNP | FPG | 1 h-PG | 2 h-PG | FINS | 1 h-INS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Z | |||||||||||||||
| rs6044695 | −2.71 | −0.36 | 0.72 | 0.84 | −1.58 | 0.11 | 0.77 | −1.63 | 0.10 | 0.31 | −0.18 | 0.86 | 0.96 | ||
| rs6044696 | 0.62 | 0.53 | 0.59 | 0.20 | 0.84 | 0.84 | −0.06 | 0.96 | 0.96 | −1.54 | 0.12 | 0.31 | −0.80 | 0.42 | 0.84 |
| rs6111506 | −0.91 | 0.36 | 0.59 | −1.18 | 0.24 | 0.42 | −0.41 | 0.69 | 0.96 | −0.44 | 0.66 | 0.87 | −0.02 | 0.98 | 0.98 |
| rs4814605 | −0.55 | 0.58 | 0.59 | −1.51 | 0.13 | 0.42 | 0.99 | 0.32 | 0.77 | −1.95 | 0.051 | 0.31 | −2.04 | 0.14 | |
| rs1078199 | −1.10 | 0.27 | 0.59 | −0.52 | 0.61 | 0.84 | −1.06 | 0.29 | 0.77 | −0.25 | 0.81 | 0.87 | 0.19 | 0.85 | 0.96 |
| rs2206447 | 0.80 | 0.43 | 0.59 | 1.14 | 0.25 | 0.42 | −0.74 | 0.46 | 0.77 | 0.97 | 0.33 | 0.59 | 2.03 | 0.14 | |
| rs890609 | −0.54 | 0.59 | 0.59 | 0.27 | 0.79 | 0.84 | −1.26 | 0.21 | 0.77 | 0.93 | 0.35 | 0.59 | 0.77 | 0.44 | 0.84 |
| rs2269023 | 2.84 | 2.95 | 0.27 | 0.79 | 0.96 | 1.70 | 0.088 | 0.31 | 2.04 | 0.14 | |||||
| rs2284912 | −2.73 | −1.59 | 0.11 | 0.42 | −0.14 | 0.89 | 0.96 | 0.19 | 0.85 | 0.87 | 0.67 | 0.50 | 0.84 | ||
| rs6080705 | 0.54 | 0.59 | 0.59 | 1.20 | 0.23 | 0.42 | −0.83 | 0.41 | 0.77 | −0.16 | 0.87 | 0.87 | 0.53 | 0.60 | 0.85 |
| SNP | 2 h−INS | HOMA−IR | HOMA−beta | AUCg | AUCi | ||||||||||
| rs6044695 | −0.76 | 0.45 | 0.92 | −2.02 | 0.18 | −0.18 | 0.86 | 0.86 | −1.03 | 0.30 | 0.55 | −0.47 | 0.64 | 0.8 | |
| rs6044696 | −0.91 | 0.36 | 0.92 | −1.34 | 0.18 | 0.45 | −1.85 | 0.064 | 0.34 | 0.55 | 0.58 | 0.65 | −1.16 | 0.24 | 0.49 |
| rs6111506 | 0.21 | 0.83 | 0.92 | −0.60 | 0.55 | 0.79 | −1.06 | 0.29 | 0.6 | −1.23 | 0.22 | 0.55 | −0.34 | 0.74 | 0.82 |
| rs4814605 | −0.72 | 0.47 | 0.92 | −1.93 | 0.053 | 0.18 | −1.03 | 0.30 | 0.6 | −0.95 | 0.34 | 0.55 | −2.27 | 0.23 | |
| rs1078199 | 0.17 | 0.86 | 0.92 | −0.47 | 0.64 | 0.8 | 0.86 | 0.39 | 0.65 | −1.06 | 0.29 | 0.55 | −0.01 | 0.99 | 0.99 |
| rs2206447 | 0.30 | 0.76 | 0.92 | 1.07 | 0.28 | 0.57 | 0.52 | 0.60 | 0.86 | 0.77 | 0.44 | 0.55 | 1.63 | 0.10 | 0.35 |
| rs890609 | 0.50 | 0.62 | 0.92 | 0.76 | 0.45 | 0.75 | 1.63 | 0.10 | 0.35 | −0.28 | 0.78 | 0.78 | 0.99 | 0.32 | 0.54 |
| rs2269023 | 0.70 | 0.48 | 0.92 | 2.18 | 0.18 | −0.23 | 0.82 | 0.86 | 2.44 | 0.15 | 2.00 | 0.23 | |||
| rs2284912 | 1.69 | 0.091 | 0.91 | −0.33 | 0.74 | 0.82 | 1.82 | 0.068 | 0.34 | −1.33 | 0.18 | 0.55 | 1.42 | 0.16 | 0.39 |
| rs6080705 | −0.10 | 0.92 | 0.92 | −0.02 | 0.98 | 0.98 | −0.26 | 0.80 | 0.86 | 0.79 | 0.43 | 0.55 | 0.63 | 0.53 | 0.76 |
All the traits were adjusted for age, gender, center, drug, environmental factors (smoking, drinking and sedentary lifestyle) and BMI.
FPG: Fasting plasma glucose concentration, 1 h-PG: 1 hr plasma glucose concentration during OGTT, 2 h-PG: 2 hr plasma glucose concentration during OGTT, FINS: fasting plasma insulin concentration, 1 h-INS: 1 hr plasma insulin concentration during OGTT, 2 h-INS: 2 hr plasma insulin concentration during OGTT, AUCg: area under curve of plasma glucose, AUCi: Area under curve of plasma insulin.
Figure 1Haploview LD graph of the PCSK2 gene (10 genotyped SNPs in this study).
Pairwise LD coefficients D′ × 100 are shown in each cell (D′ values of 1.0 are not shown). The standard color scheme of Haploview was used for the LD color display (logarithm of likelihood odds ratio [LOD] (a measure of confidence in the value of D′) ≥2 and D′ = 1, shown in bright red; LOD ≥ 2 and D′ < 1 shown in blue; LOD < 2 and D′ = 1 shown in pink; LOD < 2 and D′ < 1 shown in white).
Family-based association test of PCSK2 haplotypes with various traits of glucose homeostasis in SAPPHIRe Chinese population according to additive model.
All the traits were adjusted for age, gender, and BMI.
aHaplotype-specific P-value permutation test 10,000 times.
bWhole marker permutation test (chisq sum) 10,000 times; FPG: Fasting plasma glucose concentration; 1 h-PG: 1 hr plasma glucose concentration during OGTT; 2 h-PG: 2 hr plasma glucose concentration during OGTT; FINS: fasting plasma insulin concentration; 1 h-INS: 1 hr plasma insulin concentration during OGTT; 2 h-INS: 2 hr plasma insulin concentration during OGTT; AUCg: area under curve of plasma glucose; AUCi: area under curve of plasma insulin; “–” Z-values unavailable due to sparseness.
Incidence of progression to diabetes in normoglycemic participants at baseline according to PCSK2 SNPs using the proportional hazard model.
| No. | SNP Name | Major/Minor allele | Incident cases/100 person-year (n = No. of those progressed to diabetes) | Hazard ratio for Aa or aa vs. AA (95% C.I.)* | P | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| AA | Aa | aa | ||||||||
| 1 | rs6044695 | T/A | 2.82 | (20) | 1.33 | (11) | 0.39 | (1) | 0.28 (0.12–0.63) | |
| 2 | rs6044696 | T/C | 2 | (25) | 1.32 | (7) | 0 | (0) | 0.32 (0.12–0.83) | |
| 3 | rs6111506 | T/A | 1.9 | (8) | 1.95 | (18) | 1.34 | (6) | 0.36 (0.15–0.9) | |
| 4 | rs4814605 | G/T | 1.35 | (7) | 2.04 | (19) | 1.75 | (6) | 0.86 (0.33–2.27) | 0.76 (0.98) |
| 5 | rs1078199 | C/G | 1.59 | (15) | 2.21 | (17) | 0 | (0) | 1.05(0.47–2.35) | 0.90 (0.98) |
| 6 | rs2206447 | C/T | 2.32 | (11) | 1.89 | (17) | 0.95 | (4) | 0.64 (0.24–1.73) | 0.38 (0.98) |
| 7 | rs890609 | C/T | 2.28 | (11) | 1.89 | (17) | 0.98 | (4) | 0.7 (0.25–1.99) | 0.51 (0.98) |
| 8 | rs2269023 | C/T | 1.72 | (15) | 2.07 | (15) | 1.05 | (2) | 1.02 (0.34–3.06) | 0.98 (0.98) |
| 9 | rs2284912 | T/C | 2.4 | (27) | 0.65 | (4) | 2.06 | (1) | 0.37 (0.16–0.86) | |
| 10 | rs6080705 | C/A | 1.84 | (12) | 1.78 | (15) | 1.7 | (5) | 1.16 (0.47–2.89) | 0.74 (0.98) |
*AA: homozygote of major allele, Aa: heterozygote of major allele, aa: homozygote of minor allele.
**All the P values were adjusted for age, gender, center, drug, environmental factors (smoking, drinking and sedentary lifestyle) and BMI.
List of PCSK2 SNPs associated with type 2 diabetes or glucose homeostatic parameters according to published data or GWAS database.
| SNP name [Ref. No] | Chromosome Position | Genetic variants | Phenotype | Ethnicity | |
|---|---|---|---|---|---|
| CA repeat in intron 2 polymorphism [ref. | Chromosome 20 | (CA)15–21 | type 2 diabetes | 0.0068 [(CA)21] | Japanese |
| rs2208203 [ref. | 17,272,003 | C/T | reduced insulin secretion and lower fasting glucagon levels in non-diabetic individuals | 1.3 × 10−6 (corrected insulin response during OGTT) 1.6 × 10−7 (disposition index) 0.0048 (fasting glucagon levels) | Finland and Sweden |
| rs2021785 [ref. | 17,370,063 | C/T | Type 2 diabetes | 0.00014 | African Americans |
| rs1609659 [ref. | 17,170,735 | A/G | 0.028 | ||
| rs4814597 [ref. | 17,159,633 | G/A | 0.039 | ||
| rs2269023 [ref. | 17,381,079 | T/C | 0.043 | ||
| rs2021785 [ref. | 17,370,063 | C/T | Type 2 diabetes | 0.0335 | Han Chinese |
| rs2206447 [ref. | 17,330,737 | C/T | Type 2 diabetes | 0.007631 | Caucasian |
| rs6080705 [ref. | 17,401,598 | C/A | HOMA-beta | 0.008588 | |
| HOMA-IR | 0.02582 | ||||
| FINS | 0.01508 |